表紙
市場調査レポート

大腸炎:パイプライン分析

Colitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232843
出版日 ページ情報 英文 102 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
大腸炎:パイプライン分析 Colitis - Pipeline Review, H2 2016
出版日: 2016年07月27日 ページ情報: 英文 102 Pages
概要

大腸炎とは大腸の炎症であり、ウイルス、寄生虫、食中毒(バクテリア)などによる感染、炎症性疾患(潰瘍性大腸炎・クローン病 )、血流の不足(虚血性大腸炎)、大腸への過去の被爆などさまざまな原因があります。腹痛、鼓腸、血便、悪寒、脱水、下痢、発熱などの症状があり、非ステロイド性抗炎症薬(NSAID)、コルチコステロイドなどの治療法があります。

当レポートでは、世界における大腸炎治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 調査範囲

大腸炎の概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Aerpio Therapeutics, Inc.
  • 味の素製薬
  • Akebia Therapeutics, Inc.
  • Amorepacific Corporation
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dr. Falk Pharma GmbH
  • Galapagos NV
  • Immuron Limited
  • Innate Pharma S.A.
  • Peptinov SAS
  • Pfizer Inc.
  • Prokarium Limited
  • Protalix BioTherapeutics, Inc.
  • RDD Pharma Ltd.
  • Saniona AB
  • Synovo GmbH

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AcTMP-1
  • AKB-4924
  • AKB-6899
  • AN-346
  • 腫瘍治療用ヘパラナーザ阻害抗体
  • 大腸炎治療用抗体
  • 炎症性疾患・大腸炎治療用TNFアルファ阻害アンチセンスRNAiオリゴヌクレオチド
  • APY-0201
  • BC-1215
  • BMS-986104
  • budesonide
  • クロストリジウム・ディフィシレ・ワクチン
  • CSY-0073
  • 炎症性疾患・大腸炎治療用TRP チャネル拮抗薬
  • etanercept biosimilar
  • filgotinib
  • IMM-124E
  • IPH-33
  • mesalamine
  • NK-007
  • PAC-14028
  • Peptide to Inhibit NFkB 大腸炎・腸炎治療用
  • PF-06425090
  • PPV-06
  • RDD-2007
  • クローン病・大腸炎治療用 TNF-アルファ阻害組み換えタンパク質
  • 大腸炎治療薬
  • 大腸炎治療用 Panx1阻害合成ペプチド
  • 大腸炎治療用インターロイキン12/23標的ワクチン
  • 大腸炎治療用インターロイキン23標的ワクチン
  • ZK-216348

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8309IDB

Summary

Global Markets Direct's, 'Colitis - Pipeline Review, H2 2016', provides an overview of the Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Colitis
  • The report reviews pipeline therapeutics for Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Colitis therapeutics and enlists all their major and minor projects
  • The report assesses Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Colitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Colitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Colitis Overview
  • Therapeutics Development
    • Pipeline Products for Colitis - Overview
    • Pipeline Products for Colitis - Comparative Analysis
  • Colitis - Therapeutics under Development by Companies
  • Colitis - Therapeutics under Investigation by Universities/Institutes
  • Colitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Colitis - Products under Development by Companies
  • Colitis - Products under Investigation by Universities/Institutes
  • Colitis - Companies Involved in Therapeutics Development
    • Aerpio Therapeutics, Inc.
    • Akebia Therapeutics, Inc.
    • Amorepacific Corporation
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Cosmo Pharmaceuticals S.p.A
    • Dr. Falk Pharma GmbH
    • EA Pharma Co Ltd
    • Euroscreen S.A.
    • Genfit SA
    • Immuron Limited
    • Innate Pharma S.A.
    • Peptinov SAS
    • Pfizer Inc.
    • Prokarium Limited
    • RDD Pharma Ltd.
    • Saniona AB
    • Synovo GmbH
  • Colitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AcTMP-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AKB-4924 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AKB-6899 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-346 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody for Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APY-0201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BC-1215 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Clostridium difficile vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSY-0073 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elafibranor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ESN-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMM-124E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPH-33 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mesalamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NK-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-14028 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06425090 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PPV-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDD-2007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rifamycin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-182 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IL12 and IL23 for Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IL23 for Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-216348 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Colitis - Dormant Projects
  • Colitis - Discontinued Products
  • Colitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX
      • Jul 11, 2013: Mylan Confirms First-to-File Patent Challenge Relating to CANASA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Colitis, H2 2016
  • Number of Products under Development for Colitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Colitis - Pipeline by Aerpio Therapeutics, Inc., H2 2016
  • Colitis - Pipeline by Akebia Therapeutics, Inc., H2 2016
  • Colitis - Pipeline by Amorepacific Corporation, H2 2016
  • Colitis - Pipeline by Bayer AG, H2 2016
  • Colitis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016
  • Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
  • Colitis - Pipeline by EA Pharma Co Ltd, H2 2016
  • Colitis - Pipeline by Euroscreen S.A., H2 2016
  • Colitis - Pipeline by Genfit SA, H2 2016
  • Colitis - Pipeline by Immuron Limited, H2 2016
  • Colitis - Pipeline by Innate Pharma S.A., H2 2016
  • Colitis - Pipeline by Peptinov SAS, H2 2016
  • Colitis - Pipeline by Pfizer Inc., H2 2016
  • Colitis - Pipeline by Prokarium Limited, H2 2016
  • Colitis - Pipeline by RDD Pharma Ltd., H2 2016
  • Colitis - Pipeline by Saniona AB, H2 2016
  • Colitis - Pipeline by Synovo GmbH, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Colitis - Dormant Projects, H2 2016
  • Colitis - Dormant Projects (Contd..1), H2 2016
  • Colitis - Dormant Projects (Contd..2), H2 2016
  • Colitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Colitis, H2 2016
  • Number of Products under Development for Colitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top